Abstract
Mitochondria are known to play crucial roles in normal cellular physiology and in more recent years they have been implicated in a wide range of pathologies. Central to both these roles is their ability to alter their shape interchangeably between two different morphologies: an elongated interconnected network and a fragmented discrete phenotype - processes which are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in cardiovascular health and disease and we explore its role as a potential therapeutic target for treating cardiovascular and metabolic disease.
Keywords: Cardiovascular disease, fission, fusion, mitochondrial morphology, OPA1.
Current Drug Targets
Title:OPA1 in Cardiovascular Health and Disease
Volume: 16 Issue: 8
Author(s): Niall Burke, Andrew R. Hall and Derek J. Hausenloy
Affiliation:
Keywords: Cardiovascular disease, fission, fusion, mitochondrial morphology, OPA1.
Abstract: Mitochondria are known to play crucial roles in normal cellular physiology and in more recent years they have been implicated in a wide range of pathologies. Central to both these roles is their ability to alter their shape interchangeably between two different morphologies: an elongated interconnected network and a fragmented discrete phenotype - processes which are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in cardiovascular health and disease and we explore its role as a potential therapeutic target for treating cardiovascular and metabolic disease.
Export Options
About this article
Cite this article as:
Burke Niall, Hall R. Andrew and Hausenloy J. Derek, OPA1 in Cardiovascular Health and Disease, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150102113648
DOI https://dx.doi.org/10.2174/1389450116666150102113648 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets Early Occurrence Cases of Diabetes Mellitus: Clinical Picture in Two Major Tertiary Care Hospitals in India
Current Diabetes Reviews Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Current Medicinal Chemistry Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design Obstructive Sleep Apnea and Atrial Arrhythmogenesis
Current Cardiology Reviews Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Current Vascular Pharmacology Breath Tests to Assess Alcoholic Liver Disease
Reviews on Recent Clinical Trials HGF as Angiogenic Factor and Therapeutic Approach
Current Signal Transduction Therapy Transthyretin Deposition in Familial Amyloidotic Polyneuropathy
Current Medicinal Chemistry Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Inotropic and Vasoactive Drugs in Pediatric ICU
Current Drug Targets Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry